Herceptin Boosts Survival for Breast Cancer, Study Reports
Taking drug in addition to chemotherapy also reduces risk of cancer recurrence (Source: WebMD Health)
Source: WebMD Health - October 20, 2014 Category: Consumer Health News Source Type: news

Herceptin Boosts Survival for Breast Cancer, Study Reports
Taking drug in addition to chemotherapy also reduces risk of cancer recurrence Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 20, 2014 Category: Consumer Health News Source Type: news

Trastuzumab continues to show life for HER2-positve early stage breast cancer
(Mayo Clinic) After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2014 Category: Cancer & Oncology Source Type: news

Green tea compound may improve cancer drugs
Conclusion This study developed a new way of packaging and carrying protein drugs by combining them with a green tea extract called Epigallocatechin-3-O-gallate (EGCG), which itself may have anti-cancer properties. They formed a complex between derivatives of EGCG and the protein cancer drug Herceptin. Tests in the laboratory and in mice indicated it might have better anti-cancer properties than non-complexed free Herceptin. This is encouraging research and may lead to improvements in delivery mechanisms for protein drugs further down the line. But this research remains at a very early stage of development. The results f...
Source: NHS News Feed - October 6, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Study Shows Roche's Perjeta Extended Lives of Breast Cancer Patients by 15.7 Months
Adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 30, 2014 Category: Pharmaceuticals Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Drug should remain standard of care for HER2-positive tumors, doctors say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Title: Herceptin Best for Certain Breast Cancer Patients, Study SaysCategory: Health NewsCreated: 9/30/2014 9:35:00 AMLast Editorial Review: 9/30/2014 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 30, 2014 Category: Cancer & Oncology Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Drug should remain standard of care for HER2-positive tumors, doctors say (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - September 30, 2014 Category: Cancer & Oncology Source Type: news

New breast cancer drug cocktail shows 'unprecedented' boost to patient's lifespan
Patients given a cocktail of two drugs by Swiss firm Roche lived 15.7 months longer than those on Herceptin and chemotherapy alone. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests
Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a researcher. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 29, 2014 Category: Science Source Type: news

Hopes for new breast cancer drug
A breast cancer drug could extend the lives of patients with an advanced form of the disease by almost five years, a study has found.Women with an aggressive type of cancer which has been traditionally hard to treat could benefit from using perjeta as a combination therapy with chemotherapy and herceptin, researchers said.A trial into the effectiveness of the combination of drugs found that survival among women with previously untreated advanced HER2-positive breast cancer was e (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - September 29, 2014 Category: Nursing Source Type: news

Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
(Mayo Clinic) Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab, also known as Herceptin, should remain the standard of care for this cancer, says a Mayo Clinic researcher. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 29, 2014 Category: Cancer & Oncology Source Type: news

'Unprecedented' Survival of 15 Months Seen in CLEOPATRA'Unprecedented' Survival of 15 Months Seen in CLEOPATRA
Pertuzumab plus trastuzumab adds a 15-month survival benefit in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

16 Months' Longer Survival with Addition of Pertuzumab in Advanced Breast Cancer (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Adding pertuzumab (Perjeta) to docetaxel and trastuzumab (Herceptin) as a first-line treatment was associated with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 29, 2014 Category: Primary Care Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2014 Category: Science Source Type: news

Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche Breast Cancer Drug Perjeta Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Media News)
Source: Roche Media News - September 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2014 Category: Pharmaceuticals Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
(European Society for Medical Oncology) Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 28, 2014 Category: Biology Source Type: news

HER2 in Trastuzumab/Emtansine vs Trastuzumab/DocetaxelHER2 in Trastuzumab/Emtansine vs Trastuzumab/Docetaxel
What group of patients experience enhanced improvement from T-DM1 therapy? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 5, 2014 Category: Science Source Type: news

Cardiovascular Toxicity Associated With Adjuvant TrastuzumabCardiovascular Toxicity Associated With Adjuvant Trastuzumab
Who is at risk for cardiac toxicity associated with trastuzumab? How should patients be screened? Therapeutic Advances in Drug Safety (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 21, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Merrimack begins Phase II HERMIONE trial of MM-302 for breast cancer treatment
US-based Merrimack Pharmaceuticals has started the Phase II HERMIONE trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin) to treat patients with HER2-positive locally advanced or met… (Source: Drug Development Technology)
Source: Drug Development Technology - August 11, 2014 Category: Pharmaceuticals Source Type: news

NICE rejects Roche’s new breast cancer drug over high pricing
The NHS drug advisory body National Institute for Health and Care Excellence (NICE) has rejected Roche’s new breast cancer drug Kadcyla (trastuzumab emtansine) because of the treatment's high cost. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 10, 2014 Category: Pharmaceuticals Source Type: news

'Revolutionary' breast cancer drug denied on NHS over cost: Nice
A 'revolutionary' breast cancer drug that can give patients an extra six months of life has been turned down by the NHS drugs rationing body as it is too expensive (Source: Telegraph Health)
Source: Telegraph Health - August 8, 2014 Category: Consumer Health News Tags: rastuzumab emtansine breakthrough breast cancer Herceptin Nice her 2 Source Type: news

[Research Article] MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer
Activating a deacetylase may overcome resistance to a receptor-targeted inhibitor in some breast cancer patients. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - July 30, 2014 Category: Science Authors: Umadevi Thirumurthi, Jia Shen, Weiya Xia, Adam M. LaBaff, Yongkun Wei, Chia-Wei Li, Wei-Chao Chang, Chung-Hsuan Chen, Hui-Kuan Lin, Dihua Yu, Mien-Chie Hung Source Type: news

Aggressive breast cancer protein discovered
Conclusion This is a valuable laboratory study that furthers our understanding of the way HER2 may promote the growth, proliferation and spread of breast cancer cells, possibly through the influence of the protein integrin αvβ6. The researchers suggest up to 40% of people with HER2-positive breast cancers may also have a high expression of integrin αvβ6. The discovery that integrin αvβ6 may play a role in mediating the growth and progression of these cancers hopefully opens up new treatment possibilities for people with HER2-positive cancers. As the researchers suggest, their study supports...
Source: NHS News Feed - July 7, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

New treatment to stop spread of breast cancer
The discovery offers hope for 4,000 women diagnosed per year with HER2-positive breast cancer, who do not respond well to the current treatment, Herceptin. (Source: the Mail online | Health)
Source: the Mail online | Health - July 4, 2014 Category: Consumer Health News Source Type: news

T-DM1 Now Preferred for Progressive HER2 Breast CancerT-DM1 Now Preferred for Progressive HER2 Breast Cancer
T-DM1, a successor to trastuzumab, should be the preferred choice for HER2-positive breast cancer that has progressed despite multiple lines of treatment, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Herceptin prolongs life in advanced breast cancer, but ups risk of heart problems
But pros outweigh cons, finds Cochrane Library reviewRelated items from OnMedicaDrug cuts breast cancer by half in high-risk womenPros of Herceptin outweigh cons for breast cancer, finds studyInjectable form of Herceptin could simplify breast cancer treatmentEarly HRT may raise cancer riskNew breast cancer drug ‘unaffordable’ for NHS (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 13, 2014 Category: UK Health Source Type: news

Few Cardiac Events With Trastuzumab Treatment of Breast CancerFew Cardiac Events With Trastuzumab Treatment of Breast Cancer
Trastuzumab carries only a low risk of cardiotoxicity, a new paper reports. Patients in the study had received one or two years of trastuzumab treatment in the Herceptin Adjuvant (HERA) trial. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm
In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug Trastuzumab (Herceptin) is associated with prolonged survival but also increases the risk of developing heart problems, a new systematic review shows. However, the review concludes that more women benefit from use of Trastuzumab than are harmed. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 12, 2014 Category: Science Source Type: news

Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm
(Wiley) In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug Trastuzumab (Herceptin) is associated with prolonged survival but also increases the risk of developing heart problems, a new systematic review shows. However, the review, published in The Cochrane Library, concludes that more women benefit from use of Trastuzumab than are harmed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2014 Category: Cancer & Oncology Source Type: news

Breast Cancer Drug Herceptin Linked to Risk of Heart Problems: Study
But most of these effects reverse after women finish treatment, experts say (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 11, 2014 Category: Cancer & Oncology Source Type: news

Breast Cancer Drug Herceptin Linked to Risk of Heart Problems: Study
But most of these effects reverse after women finish treatment, experts say (Source: WebMD Health)
Source: WebMD Health - June 10, 2014 Category: Consumer Health News Source Type: news

Breast Cancer Drug Herceptin Linked to Risk of Heart Problems
But most of these effects reverse after women finish treatment, experts say Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Heart Disease in Women (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 10, 2014 Category: Consumer Health News Source Type: news

New research could provide key to overcoming resistance to HER2 targeted cancer treatments
(Trinity College Dublin) Scientists from Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments. The findings have just been published in leading international, peer reviewed journal: Cancer Research, the most frequently cited cancer journal in the world. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2014 Category: Global & Universal Source Type: news

Breast Cancer Drug Herceptin Linked to Risk of Heart Problems: Study
But most of these effects reverse after women finish treatment, experts say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 10, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Cardiology, Gynecology, Oncology, Pharmacy, News, Source Type: news

Kadmon initiates Phase Ib/IIa trial of KD019 and Trastuzumab to treat HER2+ breast cancer
US-based Kadmon has started a Phase Ib/IIa trial of KD019, an orally bioavailable small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR, in combination with trastuzumab (Herceptin) to treat HER2+ breast cancer metastasized to the brain. (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2014 Category: Pharmaceuticals Source Type: news

ASCO: Herceptin Still a Boon for Small Breast Tumors
CHICAGO (MedPage Today) -- The monoclonal antibody trastuzumab (Herceptin) was beneficial for women with small tumors, according to a new meta-analysis of the randomized trials of the drug. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 3, 2014 Category: Hematology Source Type: news

ALTTO Disappoints Clinicians and Upends ResearchALTTO Disappoints Clinicians and Upends Research
Adding lapatinib to trastuzumab does not improve outcomes in the adjuvant setting, in contrast to what was seen in the neoadjuvant setting. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GlaxoSmithKline plc (LSE: GSK) today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab as adjuvant treatment for HER2 positive early breast cancer (Source: GSK news)
Source: GSK news - June 1, 2014 Category: Pharmaceuticals Source Type: news

ALTTO test of dual HER2 blockade finds single agent remains the gold standard
(Mayo Clinic) In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib did not add benefit to the standard trastuzumab adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2014 Category: Global & Universal Source Type: news

ALTTO Test of Dual HER2 Blockade Finds Single Agent - Trastuzumab - Remains Gold Standard
http://www.youtube.com/watch?v=PAyvFbGlWKY&feature=youtu.be Journalists: Broadcast soundbites with Dr. Perez are available in the downloads. CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 1, 2014 Category: Databases & Libraries Source Type: news

Sure, We'll (Eventually) Beat Cancer. But Can We Afford To?
Matt Herper’s tour de force article in the latest Forbes magazine suggests that companies and researchers are – perhaps – turning the tables on cancer using novel immunotherapies that are producing nearly unheard of outcomes even in late stage disease. The trillion dollar question: Can we afford to win the war on cancer, given current trends in drug development and pricing? What is really remarkable about Herper’s article is how quickly the oncology field is changing.  The search for drugs over the last decade or so has focused on disrupting tumor biology through targeted therapies modeled aft...
Source: Forbes.com Healthcare News - May 17, 2014 Category: Pharmaceuticals Authors: Paul Howard Source Type: news

New ASCO Guidelines Address HER2-Positive Breast CancerNew ASCO Guidelines Address HER2-Positive Breast Cancer
New ASCO guidelines recommend HER2-targeted therapy for most patients with HER2-positive advanced breast cancer, using trastuzumab, pertuzumab, and taxane for first-line treatment. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 8, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New breast cancer drug ‘unaffordable’ for NHS
Charities disappointed at NICE’s draft decision not to recommend KadcylaRelated items from OnMedicaMortality higher if using paroxetine and tamoxifenBreast cancer rate falls with decline in HRT useData don’t support HRT for chronic disease preventionBenefit of Herceptin in more breast cancer casesDrugs regulators “put profits before patients” (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 23, 2014 Category: UK Health Source Type: news

Vials of trastuzumab stolen in Italy and redistributed in other countries under false credentials
Read the full story on MD Consult: Vials of trastuzumab stolen in Italy and redistributed in other countries under false credentials (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - April 21, 2014 Category: Journals (General) Source Type: news